Pulmonary arterial hypertension (PAH) has a multifactorial pathobiology. Vasoconstriction,
remodeling of the pulmonary vessel wall, and thrombosis contribute to increased pulmonary …

Although plasma proteins have important roles in biological processes and are the direct
targets of many drugs, the genetic factors that control inter-individual variation in plasma …

Pulmonary arterial hypertension (PAH) is caused by functional and structural changes in the
pulmonary vasculature, leading to increased pulmonary vascular resistance. The process of …

Background Most patients with familial primary pulmonary hypertension have defects in the
gene for bone morphogenetic protein receptor II (BMPR2), a member of the transforming …

Inflammatory processes are prominent in various types of human and experimental pulmonary
hypertension (PH) and are increasingly recognized as major pathogenic components of …

Background— Inflammation is a feature of pulmonary arterial hypertension (PAH), and
increased circulating levels of cytokines are reported in patients with PAH. However, to date, no …

Background— Mutations in the type II receptor for bone morphogenetic protein (BMPR-II), a
receptor member of the transforming growth factor-β (TGF-β) superfamily, underlie many …

Most patients with rare diseases do not receive a molecular diagnosis and the aetiological
variants and causative genes for more than half such disorders remain to be discovered 1 . …

Knowledge of the pathobiology of pulmonary hypertension (PH) continues to accelerate.
However, fundamental gaps remain in our understanding of the underlying pathological …

Background— By its inhibitory effect on platelet-derived growth factor signaling, imatinib
could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods …